000			04076nam a2200433 c 4500
999			_c127974 _d127974 _x1
001			127974
003			ES-MaUEC
005			20230102114326.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			200810s2020 gw | s |||| 0|eng d
020			_a9783030497019
024	7		_a10.1007/978-3-030-49701-9 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC271.R3 _b2020 EB
245	0	0	_aMolecular Targeted Radiosensitizers : _bOpportunities and Challenges _cedited by Henning Willers, Iris Eke
250			_aFirst edition 2020
264		1	_aCham, Switzerland _bSpringer International Publishing _c2020
300			_a1 recurso en línea (XI, 364 páginas) _b42 ilustraciones, 38 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aarchivo de texto _bPDF
490	0		_aCancer Drug Discovery and Development _x2196-9906
490	0		_aMedicine (SpringerNature-11650)
490	0		_aMedicine (R0) (SpringerNature-43714)
505	0		_aIntroduction to Molecular Targeted Radiosensitizers: Opportunities and Challenges -- Translating Targeted Radiosensitizers into the Clinic -- Cartography of the Radiogenome of Human Cancers -- Mechanisms and Markers of Clinical Radioresistance -- Preclinical Strategies for Testing of Targeted Radiosensitizers -- 3D Radiation Biology for Identifying Radiosensitizers -- Preclinical in vivo evaluation of novel radiosensitizers by local tumor control experiments -- Genetically Engineered Mouse Models for Studying Radiation Biology and Radiosensitizers -- Targeting the DNA Damage Response for Radiosensitization -- Targeting Tumor Metabolism to Overcome Radioresistance.-Targeting Tumor Hypoxia -- Normalizing the Tumor Microenvironment for Radiosensitization -- Radiosensitizers in the Era of Immuno-Oncology -- Index.
520	3		_aMolecular Targeted Radiosensitizers: Opportunities and Challenges provides the reader with a comprehensive review of key pre-clinical research components required to identify effective radiosensitizing drugs. The book features discussions on the mechanisms and markers of clinical radioresistance, pre-clinical screening of targeted radiosensitizers, 3D radiation biology for studying radiosensitizers, in vivo determinations of local tumor control, genetically engineered mouse models for studying radiosensitizers, targeting the DNA damage response for radiosensitization, targeting tumor metabolism to overcome radioresistance, radiosensitizers in the era of immuno-oncology, and more. Additionally, the book features discussions on high-throughput drug screening, predictive biomarkers, pre-clinical tumor models, and the influence of the tumor microenvironment and the immune system, with a specific focus on the challenges radiation oncologists and medical oncologists currently face in testing radiosensitizers in human cancers. Edited by two acclaimed experts in radiation biology and radiosensitizers, with thirteen chapters contributed by experts, this new volume presents an in-depth look at current developments within a rapidly moving field, with a look at where the field will be heading and providing comprehensive insight into the framework of targeted radiosensitzer development. Essential reading for investigators in cancer research and radiation biology.
988			_aSpringer_Medicine_2020
650		7	_2embne _9186645 _aCáncer _xRadioterapia
700	1		_aWillers, Henning _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aEke, Iris _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030497002
776	0	8	_iPrinted edition: _z9783030497026
776	0	8	_iPrinted edition: _z9783030497033
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-49701-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_dz _b11/2020 _ea _zSI